Study Title
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 & 6 Inhibitor, in Combination with Fulvestrant Compared to Chemotherapy in Women with HR Positive, HER2 Negative Metastatic Breast Cancer with Visceral Metastases
Purpose
To compare the efficacy of abemaciclib in combination with fulvestrant to that of physician’s choice of chemotherapy in patients with HR+, HER2- metastatic breast cancer with at least 1 site of visceral metastases & at least 1 line of prior Endocrine Therapy.
Eligibility
Study Process
Trial Details
Investigator:
IRB:
Western
IRB Number:
Trial Type:
NA
Sponsor:
Eli Lilly
Contact Information:
Hematology Oncology Associates